Go Pro
NASDAQ:LIPO

Lipella Pharmaceuticals 9/2/2026 Earnings Report

Lipella Pharmaceuticals logo
$0.0002 0.00 (0.00%)
As of 08/6/2026 01:01 PM Eastern

Lipella Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$1.28
Beat/Miss
N/A
One Year Ago EPS
N/A

Lipella Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.15 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lipella Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Lipella Pharmaceuticals Earnings Headlines

Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
See More Lipella Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lipella Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipella Pharmaceuticals and other key companies, straight to your email.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals (NASDAQ:LIPO), a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

View Lipella Pharmaceuticals Profile